Haemonetics (HAE) said it updated its financial reporting structure and will transition to two reportable segments from three starting in the first quarter of fiscal 2027.

Under the new structure, the plasma and blood center segments will be combined into a single reportable segment called Apheresis, while the hospital segment will be renamed MedSurg.

Haemonetics said the Apheresis segment will include supplemental disclosure for plasma and other operations.

The MedSurg segment will continue to include Haemonetics' blood management technologies and interventional technologies businesses, it said.